Cautious stance maintained, despite performance upgrade
25/11/21 -"Despite all the good work so far by Novo’s management, we maintain our cautious stance on the Danish diabetes giant. Lack of (medium-term) growth drivers outside the maturing diabetes market, ..."
Pages
71
Language
English
Published on
25/11/21
You may also be interested by these reports :
10/02/26
Even though Q4 25 operating profitability missed the street’s expectations, Astra met its full-year CER guidance. The Q4 performance was largely ...
06/02/26
Q4 ‘25 results exceeded consensus, as Lundbeck met its 2025 guidance. Strong growth for depression treatment Rexulti and migraine medicine Vyepti ...
05/02/26
The hugely discounted pricing announced by Hims & Hers for copycat pill versions of Novo’s semaglutide (for weight loss) seems perplexing, as they ...
05/02/26
The Q4 25 performance exceeded expectations, ensuring that GSK delivered on the higher end of the 2025 guidance. HIV, Respiratory, Immunology and ...